In HER2-positive breast cancer, the activation of EMT and migration pathways is often driven by growth factor signalling, including TGF-β, which has been shown to upregulate key EMT markers such as Snail, Twist, and Zeb1 [16]. Here, TGFB1 is linked to breast carcinoma.